[English]  [Pусский]  [中文]  
ctt-journal > Shorikov et al. (Abstract)

Shorikov et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 12
doi: 10.3205/ctt-2011-No12-abstract87

© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "5th Raisa Gorbacheva Memorial Meeting Hematopoietic Stem Cell Transplantation in Children and Adults", Saint Petersburg, Russia, September 18–20, 2011

Preliminary Program

Contribute a comment


High-dose chemotherapy in patients with advanced solid tumors. A single center experience

Egor V. Shorikov1,2, Igor N. Vyatkin1,2,  Andrey A. Igumenschev1,2, Larisa V. Vakhonina1,2, Natalya G. Maisheva1,2, Yulia A. Yakovleva1,2, Grigory A. Tsaur1,2, Alexander M. Popov1,2,3, Tatitana Y. Verzhbitskaya1,2,  Leonid I. Saveliev1,2,3, Larisa G. Fechina1,2

1Regional Children Hospital 1, Ekaterinburg, Russian Federation; 2Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation; 3Ural State Medical Academy, Ekaterinburg, Russian Federation

Correspondence: Egor V. Shorikov, Regional Children Hospital 1, Pediatric Oncology & Hematology Center, S. Deryabina street 32, Ekaterinburg, 620149, Russia, E-mail: cohc@spam is badbk.ru


Objective: To investigate the efficacy of auto-PBSCT in patients (pts) with advanced solid tumors.

Methods: From November 2006 till June 2011, 19 primary pts with advanced solid tumors were recruited: 5 pts with Ewing's sarcoma; 8 with high-risk neuroblastoma; 3 with medulloblastoma; 2 with hepatoblastoma, and 1 patient with PNET in the CNS. There were 10 boys and 9 girls aged from 10 to 156 months (median 66). All of them received auto-PBSCT with different high-dose chemotherapy regimens in accordance with the treatment protocol. In all patients PBSC were mobilized with G-CSF 10 µg/kg/day for 6 days and leukapheresis was performed at days 5 and 6 of G-CSF administration by cell separator. In 5 cases positive immunomagnetic selection of CD34+ harvested cells were carried out. The median number of administered CD34+ cells were 9.8×106 /kg (range 2.0 to 41×106 /kg). 

Results: All children demonstrated engraftment. The median time for a take of neutrophils after auto-PBSCT was 11 days (range 9–28). None of pts experienced organ toxicities greater than WHO grade II, or life-threatening infections. Complete remission was achieved in 8 pts; partial remission (PR) in 10 cases, and 1 patient did not respond to the therapy and died. Progressive disease (PD) in 4 pts and 4 relapses were registered at a median time of 312 days (range 184–661); 5 (26.3%) pts stayed in CR and 4 (21%) children in PR are alive with median time of 385 days (range 45–1514). All 4 children with relapse and 2 pts with PD died from tumor progression (median 408 days; range 93–716). One patient with hepatoblastoma died during a surgical operation. The remaining 2 pts with PD are alive at 627 and 791 days.

Conclusion: These preliminary results suggest auto-PBSCT as a curative therapeutic approach in patients with advanced solid tumors.

Keywords: solid tumors, PBSCT, children, CD34+ cell selection